Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer

Exclusion Criteria

• •Metastatic malignancy of any kind
• •Rheumatoid arthritis and other types of autoimmune and inflammatory joint disease
• •AI use \> 21 days prior to study enrollment
• •Known bleeding disorders
• •Current use of warfarin or other anticoagulants
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements
• •Daily use of n-3 PUFA concentrates or capsules or any other supplements that might interact with n-3 PUFA supplements if \> 375 mg per day of of eicosapentaenoic acid (EPA)/ docosahexaenoic acid (DHA) within six months of study initiation
• •Pregnant or nursing women
• •Known sensitivity or allergy to fish or fish oil
• •Unable to give informed consent